Literature DB >> 3965060

Vancomycin-induced neutropenia.

R L Mackett, D R Guay.   

Abstract

Although rare, neutropenia associated with long-term vancomycin therapy may occur. A 67-year-old woman with cellulitis and sepsis caused by Staphylococcus aureus was treated initially with cefazolin. Despite in-vitro susceptibility of the organism to this drug, the patient remained febrile, and therapy was changed to vancomycin. On day 17 of therapy with this medication neutropenia was noted; it progressed over the next 3 days, and therapy with the drug was stopped. A rise in the neutrophil count occurred within 5 days of discontinuation. Periodic monitoring of the leukocyte count during longterm vancomycin therapy is recommended.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3965060      PMCID: PMC1346502     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  9 in total

1.  Vancomycin induced neutropenia.

Authors:  H H Kesarwala; W J Rahill; N Amaram
Journal:  Lancet       Date:  1981-06-27       Impact factor: 79.321

2.  Vancomycin-induced neutropenia.

Authors:  R Strikas; J Studlo; F R Venezio; J P O'Keefe
Journal:  J Infect Dis       Date:  1982-10       Impact factor: 5.226

3.  Vancomycin-induced neutropenia.

Authors:  B C West
Journal:  South Med J       Date:  1981-10       Impact factor: 0.954

4.  Neutropenia associated with vancomycin therapy.

Authors:  C A Kauffman; P J Severance; J Silva; T K Huard
Journal:  South Med J       Date:  1982-09       Impact factor: 0.954

5.  Reversible neutropenia from vancomycin.

Authors:  C D Borland; W E Farrar
Journal:  JAMA       Date:  1979-11-30       Impact factor: 56.272

6.  Failure of vancomycin treatment in Staphylococcus aureus endocarditis. In vivo and in vitro observations.

Authors:  V Gopal; A L Bisno; F J Silverblatt
Journal:  JAMA       Date:  1976-10-04       Impact factor: 56.272

7.  Vancomycin therapy of bacterial endocarditis.

Authors:  E W Hook; W D Johnson
Journal:  Am J Med       Date:  1978-09       Impact factor: 4.965

8.  Drug-induced immunological neutropenia.

Authors:  S A Weitzman; T P Stossel
Journal:  Lancet       Date:  1978-05-20       Impact factor: 79.321

9.  Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981.

Authors:  B F Farber; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

  9 in total
  4 in total

Review 1.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

3.  Incidence of teicoplanin adverse drug reactions among patients with vancomycin-associated adverse drug reactions and its risk factors.

Authors:  Byung-Keun Kim; Jung-Hyun Kim; Kyoung-Hee Sohn; Ju-Young Kim; Yoon-Seok Chang; Sae-Hoon Kim
Journal:  Korean J Intern Med       Date:  2019-11-15       Impact factor: 2.884

4.  Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.

Authors:  Young-Il Jo; Jae-Ho Yoon; Sang-Youl Shin; Won-Chul Chang; Byung-Kook Kim; Choon-Jo Jin; Jong-Oh Song
Journal:  Korean J Intern Med       Date:  2004-03       Impact factor: 2.884

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.